Ventricular Tachycardia (VT) is a potentially life-threatening arrhythmia arising from structural heart disease, ischemic scars, genetic channelopathies or acute metabolic disturbances. Because VT requires rapid diagnosis, risk stratification and targeted therapy, clinicians often pursue specialised learning on Ventricular Tachycardia when attending electrophysiology and arrhythmia tracks at a cardiology conference. With advancements in mapping systems, ablation techniques and device-based management, this session examines the evolving field of complex ventricular-arrhythmia management.

The session begins with a review of VT mechanisms, including reentry circuits, scar-related macroreentry, triggered activity and abnormal automaticity. Participants learn how ischemic cardiomyopathy, non-ischemic cardiomyopathy, myocarditis, arrhythmogenic right-ventricular cardiomyopathy and genetic syndromes like CPVT contribute to VT development. Clinical presentations such as palpitations, presyncope, hemodynamic instability and syncope are discussed to guide initial assessment.

Diagnostic evaluation includes ECG interpretation, ambulatory monitoring, device interrogation and advanced imaging. The session highlights the use of cardiac MRI for scar assessment, CT integration for procedural planning and echocardiography for structural evaluation. Electrophysiology study and high-density mapping systems are explained to help identify arrhythmogenic substrates.

Therapeutic options include antiarrhythmic medications, catheter ablation, ICD implantation, autonomic modulation and substrate modification. Attendees examine ablation strategies such as linear lesions, scar homogenisation, substrate isolation and epicardial access in challenging cases. The session also emphasises acute-management strategies for VT storm, including beta-blockade, deep sedation and sympathetic modulation.

Long-term management focuses on reducing recurrence, optimising heart-failure therapy, monitoring for device therapies and addressing reversible triggers. Genetic testing is highlighted for inherited arrhythmia syndromes. Case-based learning illustrates decision-making for sustained VT, nonsustained VT and polymorphic presentations.

Future directions include AI-driven arrhythmia prediction, real-time mapping enhancements, pulsed-field ablation and neurocardiac modulatory technologies. By mastering these tools, clinicians gain greater confidence in evaluating and treating VT across diverse settings.